300750 CONTEMPORARY AMPEREX TECHNOLOGY CO

EQS-News: CRS appoints Catherine Canales as new Chief Commercial Officer to fuel strategic development and international growth

EQS-News: CRS Clinical Research Services Management GmbH / Key word(s): Personnel
CRS appoints Catherine Canales as new Chief Commercial Officer to fuel strategic development and international growth

10.04.2024 / 11:00 CET/CEST
The issuer is solely responsible for the content of this announcement.


 CRS appoints Catherine Canales as new Chief Commercial Officer
to fuel strategic development and international growth

Mannheim, Germany, April 10, 2024 – CRS Clinical Research Services, an expert early-phase Contract Research Organization (CRO), today announced the appointment of Catherine Canales as Chief Commercial Officer (CCO), effective today, completing the new CRS leadership team. Together, they are committed to steering the company's strategic development, growth, and innovation on a global scale.

Dr. Elisabeth Lackner, CEO of CRS, commented on the appointment: “It is a great pleasure to welcome Catherine on board the CRS management team. Catherine's induction is a pivotal moment in our pursuit of internationalization and superior service quality. Her proven expertise, forward-thinking approach, and collaborative leadership style align perfectly with CRS' needs, as we continuously adapt to the changing landscape of clinical research. Aligned with our strategy, Catherine has a strong focus on client satisfaction and positive client experiences. Together, we are poised for unparalleled growth and success.”

Catherine Canales, CCO of CRS, emphasized: “At the core of CRS’ success is a steadfast commitment to outstanding service for our clients and their patients. By adopting a leadership style that champions change and innovation, we aim to create a culture where excellence in client service is the norm. Our dedication to enhancing our team's skills will allow us to exceed our clients' expectations, thereby strengthening relationships and providing customized solutions. This commitment to excellence in service is the cornerstone of our future strategy and will propel our collective efforts towards achieving exceptional results together.”

Catherine brings over two decades of experience in the clinical research services industry to CRS. Her outstanding track record in business development, growth strategy implementation, and strategic marketing stands as a testament to her expertise. She joins from Labcorp Central Laboratory Services, where she held the position of European Sales Director, Business Development Coach, and Senior Director of Strategic Accounts, leading business development, marketing, and sales activities in the biotech sector. Prior to that, she was Senior Director, Business Development at Labcorp Drug Development (now Fortrea), responsible for the global commercial relationship for one of the company’s key accounts. Before that, she served as Director, Business Development at Premier Research, driving business growth and sales by promoting phase I-IV clinical development services. Catherine obtained a Master’s degree in Business Sciences from Lugano Business School and completed various post-graduate trainings, covering subjects ranging from marketing and executive coaching to clinical trials and regulatory affairs.

About CRS Clinical Research Services

CRS Clinical Research Services Management GmbH, a leading early-phase CRO and multi-indication specialist, operates multiple study sites across Germany with a capacity of 200 in-house beds. CRS excels in conducting clinical trials spanning from First-in-Human to Proof-of-Concept studies, demonstrating proficiency across diverse therapeutic areas.

Established in 2006, CRS has emerged as a trusted partner for biopharmaceutical companies of all sizes, offering tailored strategic outsourcing. Its specialized study sites and research facilities are renowned for their recruiting capabilities, catering to a wide range of indications, including metabolic, cardiovascular, dermatologic, and women's health studies.

At CRS, a commitment to the well-being of patients and healthy volunteers as well as respect underpin every aspect of operations, reflecting the organization's unwavering adherence to the highest ethical and medical standards. CRS ensures expedited approval times, dependable recruitment, and efficient trial conduct while maintaining rigorous standards of consistency, quality, and safety.

For further details, please visit and follow us on .

For a high-resolution image of Catherine Canales, please contact

Company Contact

CRS Clinical Research Services Management GmbH

Dr. Elisabeth Lackner
Phone: 9
E-mail:

Media Inquiries

MC Services AG
Dr. Cora Kaiser
Phone:
E-mail:



10.04.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at -news.com


1877483  10.04.2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1877483&application_name=news&site_id=research_pool
EN
10/04/2024

Underlying

300750CONTEMPORARY AMPEREX TECHNOLOGY CO

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CONTEMPORARY AMPEREX TECHNOLOGY CO

 PRESS RELEASE

EQS-News: vbw Pressemitteilung zum Koalitionsvertrag: Gute Grundlage

Emittent / Herausgeber: ibw – Informationszentrale der Bayerischen Wirtschaft e. V. / Schlagwort(e): Sonstiges/Sonstiges vbw Pressemitteilung zum Koalitionsvertrag: Gute Grundlage 10.04.2025 / 09:30 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. vbw zum Koalitionsvertrag: Gute Grundlage Brossardt: „Koalitionsvertrag schafft Planungssicherheit und setzt Wachstumsimpulse“  Bertram Brossardt, Hauptgeschäftsführer der vbw – Vereinigung der Bayerischen Wirtschaft e. V.: (München, 09.04.2025). Wir freuen uns, dass jetzt der Weg frei ist f...

 PRESS RELEASE

Aquis Stock Exchange - suspension of trading

Aquis Stock Exchange Aquis Stock Exchange - suspension of trading 10-Apr-2025 / 07:00 GMT/BST The issuer is solely responsible for the content of this announcement. The following securities are suspended from trading on the Aquis Growth Market from 08.00, 10 April 2025, at the request of the company: Richmond Hill Resources Plc Ordinary Shares Symbol: SHNJ ISIN: GB00BNTBWF32 The Regulation Department Aquis Stock Exchange Floor 2, 63 Queen Victoria Street, EC4N 4UA Tel: 0203 597 6361 Email:  Website:  Dissemination of a CORPORATE NEWS, transmitted by EQS Group.The i...

 PRESS RELEASE

EQS-News: CO2Coin one of the most successful crypto investments of the...

Issuer: Clima4Future Ltd. / Key word(s): Cryptocurrency / Blockchain/Market Launch CO2Coin one of the most successful crypto investments of the coming decades. 10.04.2025 / 04:55 CET/CEST The issuer is solely responsible for the content of this announcement.     CO2Coin is going through a phase of phenomenal growth. A year ago the price was just €1, today it is around 270 USDT - an increase in value that illustrates the enormous potential of this unique project. This development reflects the crypto community's growing interest in sustainable investments. Clima4Future Lt...

 PRESS RELEASE

EQS-News: CO2Coin eine der erfolgreichsten Krypto-Investitionen der ko...

Emittent / Herausgeber: Clima4Future Ltd. / Schlagwort(e): Kryptowährung / Blockchain/Markteinführung CO2Coin eine der erfolgreichsten Krypto-Investitionen der kommenden Jahrzehnte. 10.04.2025 / 04:55 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Der CO2Coin hat einen beeindruckenden Kursanstieg erlebt. Vor einem Jahr lag der Kurs noch bei 1 €, heute liegt er bei rund 270 USDT - eine Wertsteigerung, die das enorme Potenzial dieses einzigartigen Projekts verdeutlicht. Diese Entwicklung spiegelt das wachsende Interesse der Krypto-Com...

 PRESS RELEASE

EQS-News: Zimbabwe Government Delivers on Commitment: Compensation of ...

EQS-News: Zimbabwe Ministry of Finance, Economic Development and Investment Promotion / Key word(s): Miscellaneous Zimbabwe Government Delivers on Commitment: Compensation of Former Farm Owners under the Global Compensation Deed Commences 09.04.2025 / 20:20 CET/CEST The issuer is solely responsible for the content of this announcement. In line with the GCD agreement, the FFOs receive 1 per cent of their claim in cash, with the balance being paid through US$ denominated Treasury bonds with a 2 per cent coupon and maturities of 2 to 10 years HARARE, Zimbabwe, April 9, 2025...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch